<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880681</url>
  </required_header>
  <id_info>
    <org_study_id>double needle</org_study_id>
    <nct_id>NCT04880681</nct_id>
  </id_info>
  <brief_title>Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle</brief_title>
  <official_title>Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient-blinded randomized controlled trial evaluating length and quality of prostate&#xD;
      biopsies taken by a novel biopsy needle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate biopsy is the golden standard for prostate cancer diagnosis. Transrectal prostate&#xD;
      biopsy (TRUSbx) is the most widely used technique. The biopsy chamber of the Tru Cut needle&#xD;
      is in general 19 mm. However, it is on average filled only with 13 mm of tissue. Biopsy&#xD;
      length is strongly correlated with diagnostic accuracy of prostate cancer.&#xD;
&#xD;
      Additionally, TRUSbx has a high risk of infection due to bacteria being brought across the&#xD;
      colon wall. The investigators have shown that a new needle design reduces this bacterial&#xD;
      transfer in an ex vivo setting and a previous trial (NCT049091230) has shown non inferior&#xD;
      biopsy length when compared to the standard Tru Cut needle. A further improvement of the&#xD;
      needle has now been designed aiming to increase biopsy length and quality, with the possible&#xD;
      potential to improve prostate cancer diagnosis. This is the first human pilot aiming to&#xD;
      evaluate if biopsy length of the novel needle is superior to a standard Tru Cut biopsy needle&#xD;
      in prostate biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>60 patients eligible for prostate biopsy are randomized into 2 arms (30+30 patients) using either the novel needle and actuator device or standard Tru Cut needle and actuator device used in the clinic today. On average 12 biopsies are taken from each patient. Biopsy length (primary outcome) is evaluated by a pathologist who is blinded to device used.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patient and pathologist are unaware of which needle/device is used. All biopsies are taken from behind the back of the patient enabling masking from the patient. To assess masking success, patients will be asked to guess which device was used after the procedure is complete.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate biopsy length (measured by pathologist)</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>Length of biopsy specimen in millimeters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate biopsy fragmentation</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>The number of sections the biopsy specimen is made of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General appearance of biopsy assessed by pathologist (biopsy quality)</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>General quality of biopsy specimen on a scale from 0-3 (no biopsy, poor, good, excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate biopsy length (measured in biopsy needle chamber)</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>Length of biopsy specimen in millimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate biopsy length (measured after removal from biopsy chamber)</measure>
    <time_frame>within 21 days post biopsy</time_frame>
    <description>Length of biopsy specimen in millimeters</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain from biopsy sampling</measure>
    <time_frame>At the time of biopsy sampling</time_frame>
    <description>Numeric rating Pain Scale rating from 0-10</description>
  </other_outcome>
  <other_outcome>
    <measure>14 day complications</measure>
    <time_frame>14 days after biopsy</time_frame>
    <description>Any complications related to the biopsy (example infection, bleeding)</description>
  </other_outcome>
  <other_outcome>
    <measure>30 day complications</measure>
    <time_frame>30 days after biopsy</time_frame>
    <description>Any complications related to the biopsy (example infection, bleeding)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Novel needle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Tru Cut needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard tru cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.</intervention_name>
    <description>Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.</description>
    <arm_group_label>Novel needle</arm_group_label>
    <other_name>prostate biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)</intervention_name>
    <description>Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.</description>
    <arm_group_label>Standard Tru Cut needle</arm_group_label>
    <other_name>prostate biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for prostate biopsy&#xD;
&#xD;
          -  Signed informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - None (other than general contraindications for prostate biopsy or patient not willing to&#xD;
        participate)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas Forsvall</last_name>
    <phone>0046-42-4063121</phone>
    <email>andreas.forsvall@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <state>Scania</state>
        <zip>254 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Forsvall, MD</last_name>
      <phone>0046 42 4063121</phone>
      <email>andreas.forsvall@med.lu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1080/21681805.2021.1921024</url>
    <description>Non-inferiority clinical trial of a prototype version of the novel needle</description>
  </link>
  <link>
    <url>https://doi.org/10.1080/21681805.2021.1921023</url>
    <description>Ex vivo model demonstrating reduced bacterial translocation across colon tissue with a prototype version of the novel needle</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Genital Neoplasms, Male</keyword>
  <keyword>Urogenital Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Prostatic Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

